Please use this identifier to cite or link to this item:
|Title:||Liposome interaction with macrophages and foam cells for atherosclerosis treatment : effects of size, surface charge and lipid composition||Authors:||Tang, Jinkai
Chua, Huei Min
Nguyen, Luong T. H.
Ng, Kee Woei
|Issue Date:||2021||Source:||Tang, J., Rakshit, M., Chua, H. M., Darwitan, A., Nguyen, L. T. H., Muktabar, A., Venkatraman, S. & Ng, K. W. (2021). Liposome interaction with macrophages and foam cells for atherosclerosis treatment : effects of size, surface charge and lipid composition. Nanotechnology, 32(50), 505105-. https://dx.doi.org/10.1088/1361-6528/ac2810||Project:||M4081503.F40.710090||Journal:||Nanotechnology||Abstract:||Liposomes are potential drug carriers for atherosclerosis therapy due to low immunogenicity and ease of surface modifications that allow them to have prolonged circulation half-life and specifically target atherosclerotic sites to increase uptake efficiency. However, the effects of their size, charge, and lipid compositions on macrophage and foam cell behaviour are not fully understood. In this study, liposomes of different sizes (60 nm, 100 nm and 180 nm), charges (−40 mV, −20 mV, neutral, +15 mV and +30 mV) and lipid compositions (1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, L-a-phosphatidylcholine, and egg sphingomyelin) were synthesized, characterized and exposed to macrophages and foam cells. Compared to 100 nm neutral 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) liposomes, flow cytometry and confocal imaging indicated that cationic liposomes and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DSPC) liposomes were internalized more by both macrophages and foam cells. Through endocytosis inhibition, phagocytosis and clathrin-mediated endocytosis were identified as the dominant mechanisms of uptake. Anionic and DSPC liposomes induced more cholesterol efflux capacity in foam cells. These results provide a guide for the optimal size, charge, and lipid composition of liposomes as drug carriers for atherosclerosis treatment.||URI:||https://hdl.handle.net/10356/152845||ISSN:||0957-4484||DOI:||10.1088/1361-6528/ac2810||Rights:||© 2021 IOP Publishing Ltd. All rights reserved. This is an author-created, un-copyedited version of an article accepted for publication in Nanotechnology. IOP Publishing Ltd is not responsible for any errors or omissions in this version of the manuscript or any version derived from it. The definitive publisher authenticated version is available online at https://doi.org/10.1088/1361-6528/ac2810.||Fulltext Permission:||embargo_20221008||Fulltext Availability:||With Fulltext|
|Appears in Collections:||MSE Journal Articles|
NEWRI Journal Articles
Files in This Item:
|Liposome interaction with macrophages and foam cells for atherosclerosis treatment.pdf|
|2.05 MB||Adobe PDF||Under embargo until Oct 08, 2022|
Updated on Aug 13, 2022
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.